SML1308

KT195

≥98% (HPLC)

• Synonim(y): [4-(4′-Methoxy[1,1′-biphenyl]-4-yl)-1H-1,2,3-triazol-1-yl](2-phenyl-1-piperidinyl)-methanone
• Wzór empiryczny (zapis Hilla): C₂₇H₂₆N₄O₂
• Numer CAS: 1402612-58-1
• Masa cząsteczkowa: 438.52
• UNSPSC Code: 12352200
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: powder

Właściwości

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 5 mg/mL, clear (warmed)
• storage temp.: 2-8°C
• SMILES string: [n]3(nnc(c3)c4ccc(cc4)c5ccc(cc5)OC)C(=O)N1C(CCCC1)c2ccccc2
• InChI: 1S/C27H26N4O2/c1-33-24-16-14-21(15-17-24)20-10-12-22(13-11-20)25-19-31(29-28-25)27(32)30-18-6-5-9-26(30)23-7-3-2-4-8-23/h2-4,7-8,10-17,19,26H,5-6,9,18H2,1H3
• InChI key: OEHLNQDRVMDXQD-UHFFFAOYSA-N

Opis

Biochem/physiol Actions

KT195 is a potent (IC₅₀ = 10 nM) and selective inhibitor of α/β-hydrolase domain-containing 6 (ABHD6), a serine hydrolase that acts as an alternative hydrolase of the endocannabinoid 2-arachidonoylglycerol (2-AG). KT195 has negligible activity against other serine hydrolases such as DAGLβ and has been used as a control probe for studies of DAGLβ as well as being a probe on its own to study ABHD6. KT195 treatment of Neuro2A cells caused significant accumulation of 2-AG. KT195 also lowered interleukin-1β (IL-1β) secretion from lipopolysaccharide-treated macrophages suggesting ABHD6 involvement in this activity as well.

KT195 is a potent (IC₅₀ = 10 nM) and selective inhibitor of α/β-hydrolase domain-containing 6 (ABHD6).

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• pictograms: GHS06
• signalword: Danger
• hcodes: H301,H413
• pcodes: P264 - P270 - P273 - P301 + P310 - P405 - P501
• Hazard Classifications: Acute Tox. 3 Oral - Aquatic Chronic 4
• Klasa składowania: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable